IPOs Numbers Rise In 2024 But Dwindling Returns Could Diminish Potential In 2025

New Year Still Off To Good Start With Five Offerings

 
• By Mandy Jackson
  
Only two drug developers that went public in 2024 are still trading above their IPO values (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Scrip